An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Trial Profile

An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Volanesorsen (Primary)
  • Indications Hyperlipoproteinaemia type I
  • Focus Therapeutic Use
  • Acronyms The Approach Open Label Study
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 04 Jan 2017 Time frame of primary endpoint has been changed from 52 Weeks to 117 Weeks.
    • 04 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2018.
    • 04 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top